Equities

Qilian International Holding Group Ltd

BGM:NAQ

Qilian International Holding Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)8.08
  • Today's Change0.08 / 1.00%
  • Shares traded6.75k
  • 1 Year change+99.83%
  • Beta1.3863
Data delayed at least 15 minutes, as of Sep 19 2024 20:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Qilian International Holding Group Ltd is a China-based company mainly engaged in the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives (TCMD) product, heparin product, sausage casings and fertilizers. The Company operates through three segments: Oxytetracycline & Licorice Products and TCMD segment, Fertilizer segment and Heparin Products and Sausage Casing segment. Its main brand is Qilian Shan. The Company principally operates its businesses within the domestic market.

  • Revenue in USD (TTM)29.87m
  • Net income in USD-7.86m
  • Incorporated1970
  • Employees298.00
  • Location
    Qilian International Holding Group LtdNo. 152 Hongliang East 1St StreetNo. 1703, Tianfu New DistrictJIUQUAN 610200ChinaCHN
  • Phone+86 9 372689523
  • Websitehttp://ir.qlsyy.net/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eyenovia Inc31.41k-37.28m38.49m57.00------1,225.34-0.7897-0.78970.0007-0.04250.0013--0.0418551.05-154.24-80.31-262.28-117.70-1,489.11---118,693.60-680.950.267-40.921.20------2.68--152.20--
Natural Alternatives International, Inc.120.20m-3.31m39.87m317.00--0.474129.710.3317-0.5646-0.564620.5313.560.80913.6312.77379,183.00-2.234.90-2.565.938.8515.98-2.753.802.44-2.710.09960.00-9.913.06-76.46-20.7427.08--
Fortress Biotech Inc82.62m-49.54m43.80m186.00--2.43--0.5302-3.71-3.716.050.79150.50632.366.07444,215.10-65.90-52.50-113.69-99.4668.7763.17-130.17-236.941.24-13.401.26--11.5825.7527.42---9.37--
Aadi Bioscience Inc23.82m-65.44m46.03m70.00--0.5842--1.93-2.43-2.430.88293.200.18840.63934.96267,606.80-51.76-50.25-60.12-56.1587.18---274.77-473.973.92--0.00--60.063.85-8.68--153.54--
Immix Biopharma Inc0.00-19.02m48.86m14.00--2.04-----0.8411-0.84110.000.8710.00----0.00-86.64---100.82--------------0.00-------87.44------
Odonate Inc0.00-102.07m50.02m137.00--1,844.41-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Lexaria Bioscience Corp411.01k-4.85m50.91m5.00--5.03--123.86-0.4455-0.44550.04080.64030.0539--2.1682,202.00-63.85-95.67-65.93-96.5898.8376.98-1,185.15-1,612.76---64.960.00---11.43-12.198.31------
Earth Science Tech Inc20.30m1.98m55.41m32.0028.0617.5025.842.730.00640.00640.06580.01035.4036.44--634,456.9052.57-37.9877.89--69.4063.879.74-15.481.243.570.0261--24,526.3773.03322.25------
Eagle Pharmaceuticals Inc257.55m11.95m55.58m134.004.700.22241.700.21580.9110.91119.5919.250.65491.552.561,922,022.003.046.374.047.9869.8471.864.647.851.673.550.21780.0084.565.99513.14-8.42-49.05--
Qilian International Holding Group Ltd29.87m-7.86m57.81m298.00--1.32--1.94-1.10-1.104.186.070.52373.7325.96100,236.40-14.432.71-17.013.862.9211.66-27.562.726.06-0.75270.0026.11-28.35-1.60-822.64--12.86--
SCYNEXIS Inc9.67m-35.39m59.43m29.00--0.9839--6.15-0.735-0.7350.20051.600.0736--0.7011333,344.80-26.95-30.02-31.99-36.35-55.82---366.09-86.76----0.1747--2,652.72252.64206.74------
United-Guardian, Inc.12.31m3.25m66.76m25.0020.575.5119.925.420.70650.70652.682.640.95754.127.65492,387.2025.2529.8428.6734.3950.6655.3126.3728.796.99--0.0097.37-14.28-4.140.4616-9.9217.19-19.73
CEL-SCI Corp0.00-29.10m68.87m43.00--7.17-----0.5806-0.58060.000.15620.00-------100.88-70.19-124.78-78.31-------15,434.150.1793-36.790.5517------13.99--223.59--
Cellectar Biosciences Inc0.00-50.98m75.28m20.00--7.66-----3.17-3.170.000.7890.00----0.00-176.58-83.69-295.36-99.80-----------4.810.00-------32.80--17.55--
Journey Medical Corp77.68m843.00k75.40m58.0051.009.0718.390.9707-0.0131-0.01313.910.56421.152.365.711,339,328.001.25--5.17--66.79--1.09--1.082.000.6682--7.48--87.00------
Data as of Sep 19 2024. Currency figures normalised to Qilian International Holding Group Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.08%Per cent of shares held by top holders
HolderShares% Held
UBS Securities LLCas of 30 Jun 20245.35k0.08%
Morgan Stanley & Co. LLCas of 30 Jun 2024358.000.01%
G1 Execution Services LLCas of 30 Jun 20240.000.00%
Geode Capital Management LLCas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.